Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526383 | 0.78 | MAPT (0.58) | LMNAMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL25033085 | 0.78 | CA12 (0.51) | LMNAMAPTHPGDSRCHKDC1 | |
| SCHEMBL19566788 | 0.76 | LMNA (0.62) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Ammonia Solution, Strong SCHEMBL28486254 | 0.75 | MAPT (0.56) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9181167 | 0.75 | MAPT (0.56) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Ammonia Solution, Strong SCHEMBL28483632 | 0.75 | MAPT (0.56) | LMNAMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL10311851 | 0.74 | HPGD (0.38) | LMNAMAPTHPGDSRCALDH1A1 | |
| SCHEMBL14045179 | 0.74 | MTNR1B (0.47) | MAPTALDH1A1 | |
| SCHEMBL3795380 | 0.72 | MAPT (0.48) | LMNAMAPTADRA2AADRA2BADRA2C | |
| SCHEMBL2643228 | 0.72 | MAPT (0.54) | LMNAMAPTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | LMNA 3600/4885MAPT 1313/4885ADRA2A 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.